Company news
Evolus, Inc. Common Stock (NASDAQ:EOLS) news
Every Evolus, Inc. Common Stock press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
August 4, 2026
Evolus to Report Second Quarter Financial Results on August 5, 2026
July 22, 2026
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectab...
July 8, 2026
Evolus to Participate in The Jefferies Global Healthcare Conference
May 19, 2026
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
May 11, 2026
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirm...
May 4, 2026
Evolus to Report First Quarter Financial Results on May 4, 2026
April 14, 2026
Telix Appoints David Gill as Non-Executive Director
April 1, 2026
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
March 31, 2026
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Su...
March 3, 2026
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Su...
March 3, 2026
Evolus to Participate in The Leerink Partners Global Healthcare Conference
February 25, 2026
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
February 17, 2026
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
January 9, 2026
Evolus Reports Third Quarter 2025 Financial Results
November 5, 2025
Evolus to Participate in 2025 Stifel Healthcare Conference
October 28, 2025
Evolus to Report Third Quarter Financial Results on November 5, 2025
October 22, 2025
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
October 13, 2025
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
September 22, 2025
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2025
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
September 8, 2025
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
August 25, 2025
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hy...
August 20, 2025
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 5, 2025
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
July 31, 2025
Evolus to Report Second Quarter Financial Results on August 5, 2025
July 22, 2025
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
July 9, 2025
Evolysse™ Recognized in 2025 Shape Skin Awards
June 10, 2025
Evolus Announces Departure of its Chief Financial Officer
May 27, 2025
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
May 22, 2025
Evolus Reports First Quarter 2025 Results
May 7, 2025
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
May 5, 2025
Evolus to Report First Quarter Financial Results on May 7, 2025
April 23, 2025
Evolus Announces Commercial Launch of Evolysse™
April 16, 2025
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
April 15, 2025
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
April 15, 2025
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
March 25, 2025
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
March 4, 2025
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
February 27, 2025
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
February 20, 2025
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
February 18, 2025
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
February 13, 2025
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’...
January 21, 2025
Evolus Reports Third Quarter 2024 Results
November 6, 2024
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
October 31, 2024
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
October 29, 2024
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
September 6, 2024
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
July 31, 2024
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
July 30, 2024